HemoShear Therapeutics discovers novel biological targets and advances drug programs to treat metabolic disorders with significant unmet patient need. HemoShear’s proprietary drug discovery platform, REVEAL-TX™, enables HemoShear to create best-in-class, biologically relevant human disease models to uncover and explain the underlying mechanisms of disease, translate those discoveries into drug candidates, and predict which drug candidates will treat patients successfully. HemoShear’s current drug discovery programs are focused on several rare inborn errors of metabolism and nonalcoholic steatohepatitis (NASH).

We invite you to access the latest news and information about HemoShear Therapeutics.